Key Stats for Kimberly-Clark Stock
- Current Price: $96.13
- Target Price (Mid): $159.76
- Street Target: $113.69
- Potential Total Return: +66.2%
- Annualized IRR: 11.30% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Consumer staples investors have had a difficult year with Kimberly-Clark (KMB).
KMB hit a max drawdown of 33.80% as of April 2, 2026, sliding from a 52-week high of $144.31 to $96.13, just above its 52-week low of $94.54.
Bulls argue the selloff is overdone for a company generating roughly $1.6 billion in annual free cash flow with more than 50 consecutive years of dividend increases. Bears counter that two unresolved deals, a restructured revenue base, and commodity cost pressure make this a value trap.
The central question: can Kimberly-Clark execute a transformation of this scale while keeping the financial profile that justified owning the stock?
When Kimberly-Clark reported Q4 2025 results on January 27, 2026, adjusted EPS of $1.86 beat the consensus estimate of $1.81. Revenue of $4.08 billion came in flat year over year and in line with expectations. The stock still fell 1.09% on the day.
Full-year 2025 net sales of $16.4 billion were down from $20.1 billion in 2024, primarily due to the segment restructuring, which removed the company’s international tissue and professional businesses from reported results.
Chairman and CEO Michael Hsu called 2025 “a pivotal year in the company’s more than 150-year history,” citing innovation, brand investment, and cost discipline as proof the underlying business is strengthening.
See historical and forward estimates for Kimberly-Clark stock (It’s free!) >>>
Is Kimberly-Clark Undervalued Today?
At $96.13, KMB trades at 12.68x NTM earnings and 10.44x NTM EV/EBITDA (enterprise value to earnings before interest, taxes, depreciation, and amortization), with a 5.4% dividend yield.
For a company whose brands, Huggies, Kleenex, Cottonelle, and Depend, hold the No. 1 or No. 2 market share position in approximately 70 countries, that multiple is lean.
Procter & Gamble trades at 14.52x NTM EV/EBITDA and Colgate-Palmolive at 14.69x. Even Clorox, which carries its own operational challenges, trades at 11.16x. KMB’s 10.44x sits at a discount to all three.
Whether that discount reflects fair compensation for execution risk or an overreaction is what the next two quarters will answer.
Most of the pressure traces to two simultaneous transactions. In November 2025, KMB announced a $48.7 billion agreement to acquire Kenvue, the consumer health company behind Tylenol, Neutrogena, and Listerine. Shareholders from both companies approved the deal in January 2026, and closing is targeted for the second half of 2026.
KMB projects accretion to adjusted EPS by year two post-close, backed by $2.1 billion in targeted annual EBITDA run-rate synergies.
The company has also guided for up to mid-single-digit dilution to adjusted EPS in 2027 versus its standalone plan, reflecting debt costs, deal amortization, and reinvestment timing.
Separately, Britain’s Competition and Markets Authority (CMA) launched a Phase 1 investigation on March 27, 2026, into KMB’s $3.4 billion tissue joint venture with Brazilian pulp producer Suzano.
Under the terms, Suzano acquires a 51% controlling stake in KMB’s international tissue operations for approximately $1.734 billion in cash, with KMB retaining 49%. The CMA must issue its Phase 1 decision by May 28, 2026. A Phase 2 escalation would delay the mid-2026 closing target and push back the financial benefits of that restructuring.
Neither deal changes the core setup.
The 5.4% dividend yield is at its highest level in years, supported by a net debt-to-EBITDA ratio of 1.96x.
Management’s 2026 guidance calls for organic sales growth in line with or above the roughly 2% category growth rate and double-digit adjusted EPS growth from continuing operations on a constant-currency basis. If both deals close as planned, the regulatory overhang will clear by Q3 2026.
See how Kimberly-Clark performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $96.13
- Target Price (Mid): $159.76
- Potential Total Return: +66.2%
- Annualized IRR: 11.30% / year
See analysts’ growth forecasts and price targets for Kimberly-Clark stock (It’s free!) >>>
The TIKR mid-case model targets $159.76 by December 31, 2030. The two primary revenue drivers are a 3.7% annual revenue CAGR, supported by personal care volume growth and the Kenvue integration, and net income margin expansion to 14.5% from the current LTM level of 12.3%, driven by the $2.1 billion synergy program and cost discipline.
The upside path is clear: both deals close on schedule, the CMA raises no material objections, and KMB’s personal care brands sustain volume-led organic growth. In that scenario, improved earnings visibility and a compressed multiple create conditions for a re-rating toward peers. The downside is equally defined: integration delays, cost overruns, or a Phase 2 CMA escalation push the earnings recovery timeline out, and the stock stays range-bound.
The Street target of $113.69, set by 15 analysts with a breakdown of 3 Buys, 3 Outperforms, 8 Holds, and 1 Sell as of March 31, 2026, sits 18.3% above the current price but roughly $46 below the TIKR model’s 2030 projection. The Street is pricing near-term execution risk. The TIKR model captures the longer-term margin expansion and multiple recovery cases.
Conclusion: Watch North America’s personal care organic sales at the Q1 2026 report on April 28, 2026. If that segment sustains growth at or above 2%, it confirms the core business is gaining momentum independent of the deal outcomes. KMB carries real uncertainty at current levels, but at a 10.44x forward EBITDA multiple and a 5.4% yield, the market is already demanding a premium to hold it through the noise.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Kimberly-Clark?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Kimberly-Clark, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Kimberly-Clark alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Kimberly-Clark on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
